Evolet Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 22.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 21.40 Cr
as on 16-11-2024
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 Cr
as on 16-11-2024
- Satisfied Charges ₹ 8.40 Cr
as on 16-11-2024
- Revenue 47.05%
(FY 2023)
- Profit 39.54%
(FY 2023)
- Ebitda 36.82%
(FY 2023)
- Net Worth 21.21%
(FY 2023)
- Total Assets 20.73%
(FY 2023)
About Evolet Pharmaceuticals
The Corporate was formerly known as Anchal Lifescience Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 22.00 Cr and a paid-up capital of Rs 21.40 Cr.
The company currently has active open charges totaling ₹2.00 Cr. The company has closed loans amounting to ₹8.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Evolet Pharmaceuticals Private Limited India is Vijay Gautam as COMPANY SECRETARY. Akobir Zohidov, Ilkhomzhon Mirzoev, Jamshed Mirzoev, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230DL2005PTC322716
- Company No.
322716
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Evolet Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Gautam  | Company Secretary | 25-Mar-2021 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Akobir Zohidov | Director | 04-Nov-2016 | Current |
Ilkhomzhon Mirzoev  | Director | 27-Jul-2021 | Current |
| Jamshed Mirzoev | Director | 08-May-2019 | Current |
| Safarali Safarov | Director | 18-Feb-2022 | Current |
Financial Performance of Evolet Pharmaceuticals.
Evolet Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.05% increase. The company also saw a substantial improvement in profitability, with a 39.54% increase in profit. The company's net worth Soared by an impressive increase of 21.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Evolet Pharmaceuticals?
In 2023, Evolet Pharmaceuticals had a promoter holding of 34.71% and a public holding of 65.29%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 Jan 2018 | ₹2.00 Cr | Open |
Axis Bank Ltd. Creation Date: 01 Mar 2013 | ₹1.00 M | Satisfied |
Axis Bank Limited Creation Date: 07 Dec 2012 | ₹1.90 Cr | Satisfied |
How Many Employees Work at Evolet Pharmaceuticals?
Evolet Pharmaceuticals has a workforce of 88 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Evolet Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Evolet Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
